These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32015512)

  • 1. Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis.
    Trigg RM; Turner SD; Shaw JA; Jahangiri L
    Br J Cancer; 2020 Mar; 122(7):1077-1084. PubMed ID: 32015512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
    Yagyu S; Iehara T; Tanaka S; Gotoh T; Misawa-Furihata A; Sugimoto T; London WB; Hogarty MD; Teramukai S; Nakagawara A; Hiyama E; Maris JM; Hosoi H
    PLoS One; 2016; 11(8):e0161039. PubMed ID: 27513929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
    Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
    J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patients.
    Iehara T; Yagyu S; Gotoh T; Ouchi K; Yoshida H; Miyachi M; Kikuchi K; Sugimoto T; Hosoi H
    Jpn J Clin Oncol; 2019 Aug; 49(8):743-748. PubMed ID: 31053863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
    Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
    J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
    Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
    Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative assessment of copy number alterations by liquid biopsy for neuroblastoma.
    Shirai R; Osumi T; Sato-Otsubo A; Nakabayashi K; Ishiwata K; Yamada Y; Yoshida M; Yoshida K; Shioda Y; Kiyotani C; Terashima K; Tomizawa D; Takasugi N; Takita J; Miyazaki O; Kiyokawa N; Yoneda A; Kanamori Y; Hishiki T; Matsumoto K; Hata K; Yoshioka T; Kato M
    Genes Chromosomes Cancer; 2022 Nov; 61(11):662-669. PubMed ID: 35655408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
    Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma circulating cell-free MYCN gene: A noninvasive and prominent recurrence monitoring indicator of neuroblastoma.
    Liang Y; Liu Y; Zhang P; Zhang M; Du B; Cheng W; Yu Z; Li L; Wang H; Hou G; Zhang X; Zhang W
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1688. PubMed ID: 35892165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.
    Su Y; Wang L; Zhao Q; Yue Z; Zhao W; Wang X; Duan C; Jin M; Zhang D; Chen S; Yin J; Qiu L; Cheng X; Xu Z; Ma X
    Mol Oncol; 2020 Nov; 14(11):2884-2893. PubMed ID: 32896084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma.
    Yagyu S; Gotoh T; Iehara T; Miyachi M; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tamura S; Tsuchiya K; Imamura T; Misawa-Furihata A; Sugimoto T; Sawada T; Hosoi H
    Clin Cancer Res; 2008 Nov; 14(21):7011-9. PubMed ID: 18980997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.
    Berbegall AP; Bogen D; Pötschger U; Beiske K; Bown N; Combaret V; Defferrari R; Jeison M; Mazzocco K; Varesio L; Vicha A; Ash S; Castel V; Coze C; Ladenstein R; Owens C; Papadakis V; Ruud E; Amann G; Sementa AR; Navarro S; Ambros PF; Noguera R; Ambros IM
    Br J Cancer; 2018 May; 118(11):1502-1512. PubMed ID: 29755120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
    Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of neuroblastoma stage on serum-based detection of MYCN amplification.
    Combaret V; Hogarty MD; London WB; McGrady P; Iacono I; Brejon S; Swerts K; Noguera R; Gross N; Rousseau R; Puisieux A
    Pediatr Blood Cancer; 2009 Sep; 53(3):329-31. PubMed ID: 19301388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A MYCN-independent mechanism mediating secretome reprogramming and metastasis in
    Zhang HF; Delaidelli A; Javed S; Turgu B; Morrison T; Hughes CS; Yang X; Pachva M; Lizardo MM; Singh G; Hoffmann J; Huang YZ; Patel K; Shraim R; Kung SHY; Morin GB; Aparicio S; Martinez D; Maris JM; Bosse KR; Williams KC; Sorensen PH
    Sci Adv; 2023 Aug; 9(34):eadg6693. PubMed ID: 37611092
    [No Abstract]   [Full Text] [Related]  

  • 16. Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma.
    Kobayashi K; Mizuta S; Yamane N; Hamabata T; Maihara T; Usami I; Heike T
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e165-e168. PubMed ID: 32032241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.
    Iehara T; Hosoi H; Akazawa K; Matsumoto Y; Yamamoto K; Suita S; Tajiri T; Kusafuka T; Hiyama E; Kaneko M; Sasaki F; Sugimoto T; Sawada T
    Br J Cancer; 2006 May; 94(10):1510-5. PubMed ID: 16670717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction.
    Peitz C; Sprüssel A; Linke RB; Astrahantseff K; Grimaldi M; Schmelz K; Toedling J; Schulte JH; Fischer M; Messerschmidt C; Beule D; Keilholz U; Eggert A; Deubzer HE; Lodrini M
    J Mol Diagn; 2020 Nov; 22(11):1309-1323. PubMed ID: 32858250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint metabolomics and transcriptomics analysis systematically reveal the impact of MYCN in neuroblastoma.
    Du B; Zhang Y; Zhang P; Zhang M; Yu Z; Li L; Hou L; Wang Q; Zhang X; Zhang W
    Sci Rep; 2024 Aug; 14(1):20155. PubMed ID: 39215128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.